BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28817119)

  • 21. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma.
    Zhang T; Liu W; Zeng XC; Jiang N; Fu BS; Guo Y; Yi HM; Li H; Zhang Q; Chen WJ; Chen GH
    Biomed Pharmacother; 2016 Dec; 84():583-591. PubMed ID: 27694002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
    Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
    Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
    Liu X; Zhang A; Xiang J; Lv Y; Zhang X
    Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
    Jin Y; Wang J; Han J; Luo D; Sun Z
    Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
    Hu Y; Yang C; Yang S; Cheng F; Rao J; Wang X
    Cell Death Dis; 2018 Sep; 9(10):954. PubMed ID: 30237408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma.
    Teng F; Zhang JX; Chang QM; Wu XB; Tang WG; Wang JF; Feng JF; Zhang ZP; Hu ZQ
    J Exp Clin Cancer Res; 2020 Nov; 39(1):235. PubMed ID: 33168027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
    Xia H; Ooi LL; Hui KM
    PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
    Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
    Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
    Quan H; Li B; Yang J
    Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression.
    Fang JH; Zhou HC; Zeng C; Yang J; Liu Y; Huang X; Zhang JP; Guan XY; Zhuang SM
    Hepatology; 2011 Nov; 54(5):1729-40. PubMed ID: 21793034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-186 modulates hepatocellular carcinoma cell proliferation and mobility via targeting MCRS1-mediated Wnt/β-catenin signaling.
    Wang H; Ou J; Jian Z; Ou Y
    J Cell Physiol; 2019 Dec; 234(12):23135-23145. PubMed ID: 31140612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Long Non-Coding RNA CASC2 Suppresses Cell Viability, Migration, and Invasion in Hepatocellular Carcinoma Cells by Directly Downregulating miR-183.
    Sun J; Liu L; Zou H; Yu W
    Yonsei Med J; 2019 Oct; 60(10):905-913. PubMed ID: 31538425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-639 is Down-Regulated in Hepatocellular Carcinoma Tumor Tissue and Inhibits Proliferation and Migration of Human Hepatocellular Carcinoma Cells Through the KAT7/Wnt/β-Catenin Pathway.
    Bai Z; Xia X; Lu J
    Med Sci Monit; 2020 Jan; 26():e919241. PubMed ID: 31955177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways.
    Fang F; Song T; Zhang T; Cui Y; Zhang G; Xiong Q
    Oncotarget; 2017 May; 8(19):31745-31757. PubMed ID: 28423650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
    Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
    Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-β signaling pathway via targeting TGFBR1.
    Zhang Y; Shi K; Liu H; Chen W; Luo Y; Wei X; Wu Z
    Acta Biochim Biophys Sin (Shanghai); 2020 May; 52(5):554-562. PubMed ID: 32324847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
    Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
    Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner.
    Huang Z; Wen J; Yu J; Liao J; Liu S; Cai N; Liang H; Chen X; Ding Z; Zhang B
    J Exp Clin Cancer Res; 2020 Aug; 39(1):150. PubMed ID: 32746934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F; Yin LX
    Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.